✦ LIBER ✦

Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome

✍ Scribed by S. MANOLAKOPOULOS; S. BETHANIS; J. ELEFSINIOTIS; S. KARATAPANIS; C. TRIANTOS; G. SOURVINOS; G. TOULOUMI; M. ECONOMOU; J. VLACHOGIANNAKOS; D. SPANDIDOS; A. AVGERINOS; D. TZOURMAKLIOTIS

Book ID: 108604448
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 134 KB
Volume: 23
Category: Article
ISSN: 0269-2813
DOI: 10.1111/j.1365-2036.2006.02806.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical outcome of HBeAg-negative chron

Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine

✍ Dr. Vito Di Marco; Alfredo Marzano; Pietro Lampertico; Pietro Andreone; Teresa S 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 869 KB

The effect of lamivudine treatment on the outcome of patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis is unclear. In a retrospective multicenter study, we have analyzed the virological events observed during lamivudine therapy in patients with HBeAgnegative chronic hepatitis an

Long-term follow-up of peginterferon and

Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B

✍ Henry Lik-Yuen Chan; Alex Yui Hui; Vincent Wai-Sun Wong; Angel Mei-Ling Chim; Ma 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB 👁 2 views

We have previously demonstrated that combination peginterferon and lamivudine treatment has superior antiviral efficacy to lamivudine monotherapy in chronic hepatitis B. In this study, we investigated the long-term posttreatment virological response to this combination treatment. Sustained virologic

Combination of Lamivudine and adefovir t

Combination of Lamivudine and adefovir therapy in HBeAg-positive chronic hepatitis B patients with poor response to adefovir monotherapy

✍ L.-C. Wang; E.-Q. Chen; J. Cao; L. Liu; J.-R. Wang; B.-J. Lei; H. Tang 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB

Clinical course and predictive factors o

Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients

✍ Mashu Aizawa; Akihito Tsubota; Kiyotaka Fujise; Keiko Tatsuzawa; Midori Kono; Sa 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 1 views

## Abstract The aims of this study were to assess the long‐term efficacy of lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy in patients with chronic hepatitis B resistant to LAM, to identify predictive factors of complete viral response (HBV‐DNA <2.6 log copies/ml at 12 months of

Outcome of hepatitis B e antigen–negativ

Outcome of hepatitis B e antigen–negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine

✍ George V. Papatheodoridis; Evangelini Dimou; Konstantinos Dimakopoulos; Spilios 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 415 KB 👁 1 views

We determined the clinical outcome of hepatitis e antigen (HBeAg)-negative chronic hepatitis B patients treated with long-term nucleos(t)ide analog therapy starting with lamivudine. We evaluated 201 such patients treated for 3.8 ؎ 1.4 years and 2 historical similar cohorts: 1 treated with interferon

Long-term outcomes of thymosin-α1 and in

Long-term outcomes of thymosin-α1 and interferon α-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B

✍ Murat Saruc; Nuri Ozden; Nurten Turkel; Semin Ayhan; Lynette M. Hock; Isil Tuzcu 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 179 KB 👁 1 views

Hepatitis B e antibody (HbeAb) and hepatitis B virus (HBV) DNA positive chronic hepatitis is a clinical entity, distinct from classical hepatitis B e antigen (HbeAg) positive chronic hepatitis B. Our aim was to evaluate the long-term therapeutic efficacy of the combination of interferon alpha-2b and